Although CD4 T cells and MHC-II neoAgs are critical components of anti-tumor immunity,23,27,28,56,92–94 we chose to utilize an SLP vaccine against a single MHC-I neoAg to definitively link the MHC-I neoAg vaccine response to a specific defined neoAg. Here, CD4 is linked to neoplasm.